Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNH - Novartis
novartis.comSubmitted by novartiscom2341 in business
Ad hoc announcement pursuant to Art. 53 LR Ad hoc announcement pursuant to Art. 53 LR Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide.